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Abstract  
Introduction: approximately eighty million people around the world are living with hepatitis C, and 700,000 people die every year, due to hepatitis 
C related complications. In Seychelles, a total of 777 cases of hepatitis C were reported from 2002 to 2016, but up to mid of 2016, the cases were 
not being treated. Treatment with Harvoni, a combination of sofosbuvir and ledipasvir (SOF/LDV), is now being offered on the condition that the 
patient does not, or has stopped, injecting drugs. This paper is the first to establish the cost effectiveness of treating all cases of hepatiti s C in 
Seychelles with Harvoni, as compared to no treatment. Methods: data extracted from literature was used to populate an economic model to calculate 
cost-effectiveness from Seychelles' government perspective. The model structure was also informed by the systematic review and an accompanying 
grading of economic models using the Consolidated Health Economic Evaluation Reporting Standard (CHEERS) checklist. A Markov model was 
developed, employing a lifetime horizon and costs and benefits were analysed from a payer's perspective and combined into incremental cost 
effectiveness ratios (ICERs). Results: the direct-acting antiviral (DAA), Harvoni, was found to be cost-saving in Seychelles hepatitis C virus (HCV) 
cohort, as compared to no treatment, with an ICER of € 753.65/QALY. The treatment was also cost-saving when stratified by gender, with the ICER 
of male and female being € 783.74/QALY and € 635.20/QALY, respectively. Moreover, the results obtained from acceptability curves showed that 
treating patients with Harvoni is the most cost-effective option, even for low thresholds. Conclusion: treating hepatitis C cases in Seychelles is cost-
saving. It is worth developing a treatment programme to include all cases of hepatitis C, regardless of status of drug injection. 
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Introduction 
 
The World Health Organization estimates that over 80 million people 
worldwide are living with chronic infection of hepatitis C (HCV), with 
a global prevalence of 1.1% [1]. Every year, more than 700,000 
deaths occur due to complications related to hepatitis C, such as liver 
cirrhosis, liver failure and hepatocellular carcinoma [1]. Up to 2014, 
the mainstay of hepatitis C treatment in high income countries was 
weekly PEGylated interferon for 24-28 weeks, along with ribavirin for 
about six months [1]. The cure rates were less than 50%, the regimen 
was expensive, and there were significant side effects, such as 
headaches, muscle aches and fever [1]. The first all oral HCV 
treatment, direct-acting antivirals (DAAs), were approved by the 
European commission in January 2014 [2]. The side effects of DAAs 
are minimal, and the cure rates are more than 90% after 12 weeks 
of treatment, regardless of co-morbidities or stage of disease of the 
patient [1]. Several countries have now updated their treatment 
programmes [1]. Despite this revolution in the treatment, hepatitis C 
elimination still faces several barriers. Firstly, the cost of the DAAs are 
high for both individuals and health systems [1]. Secondly, the access 
to treatment is lower than ideal for those who are known to be at 
higher risk of getting infected, such as people who inject drugs 
(PWID) [3]. PWID are a high-risk group due to the transmission of 
hepatitis C virus through sharing of needles during drug use [4]. DAAs 
are now recognised as the recommended treatment for hepatitis C 
worldwide [5]. The World Health Organization (WHO) has released 
updated screening and treatment guidelines to assist countries in 
making decisions while developing their treatment protocols [5]. In 
May 2016, the World Health Assembly (WHA) adopted a strategy to 
reduce hepatitis C incidence by 90% and reduce mortality by 65% by 
2030 [6]. To achieve these targets, prevention and treatment 
programmes will have to be scaled up [1, 6]. In the context of 
treatment, the requirement is to place 80% of patients with chronic 
hepatitis C on treatment [1, 6]. However, the barriers, as mentioned 
earlier, need to be addressed. 
  
Seychelles is a group of islands in the Indian Ocean, just off the east 
coast of mainland Africa. It had a total estimated population of 94,205 
at the end of 2016, the smallest of any African nation [7]. The country 
has universal healthcare that is publicly funded for all citizens [8]. 
Under the umbrella of the Public Health Agency (PHA), the 
Communicable Disease Control Unit (CDCU) is the only Specialist 
Referral Centre (SRC) in Seychelles for management of communicable 
diseases, including hepatitis C [8]. The first positive diagnostic test 
result for hepatitis C in Seychelles was in 2002 [9]. Between 2002 and 
2016, a total of 777 cases were reported, of which 648 cases (83%) 
were males and 129 cases (17%) were females [9]. The key 
population group most at risk are people who inject drugs (PWID), 
making up 99% of the hepatitis C cases recorded [9]. Furthermore, 
16% were co-infected with both hepatitis C and HIV [9]. In this same 
time frame, there were 26 (3%) hepatitis C related deaths, of which 
16 were males and 10 were females [9]. Figure 1 shows the 
increasing trend in hepatitis C incidence in Seychelles, from 2008 to 
2016. The DAA Harvoni was introduced into the hepatitis C treatment 
options as of June 2016 [10]. Thirty patients have initiated treatment 
with it in the first year [10]. Harvoni is a combination of sofosbuvir 
and ledipasvir (SOF/LDV), produced by Gilead Sciences [1]. It is now 
the recommended treatment for HCV infection with genotypes 1, 4, 5 
and 6 [1, 5]. Seychelles has access to Harvoni, at the cost of $800 for 
8 weeks course, and $1200 for 12 weeks course, for each patient 
[10]. The current recommended duration of treatment for Harvoni is 
12 weeks, regardless of viral load [5]. Treatment provision in 
Seychelles is prioritised for those who have stopped, injecting drugs 
[10]. Persons still injecting drugs continue to have limited access to 
treatment for hepatitis C [10]. Their high risk of re-infection together 
with the high cost of the current treatment plays a major role here 
[10]. We aimed to evaluate the cost effectiveness of treating all the 
hepatitis C cases in the Seychelles population, in comparison to not 
treating these cases. 
 
 
Methods 
 
A systematic review was carried out, using MEDLINE (Ovid), Embase 
(Ovid) and University of York Centre for Reviews and Dissemination, 
and data was extracted from the 21 identified studies. Transition 
probabilities and utility values used were extracted from literature. 
The EuroQol 5 dimensions questionnaire was used to report utilities. 
Evidence from the systematic review was used to populate an 
economic model to calculate cost-effectiveness from Seychelles' 
Government perspective. The model structure was also informed by 
the systematic review and an accompanying grading of economic 
models using the Consolidated Health Economic Evaluation Reporting 
Standard (CHEERS) checklist. The economic model used was a 
Markov model, accompanied by a lifetime horizon and a payer's 
perspective, as shown in Figure 2. Outcome measures included 
quality adjusted life years (QALYs) and incremental cost effectiveness 
ratios (ICERs). Two simulated cohorts, a treatment cohort (Rx cohort) 
 Page number not for citation purposes     3 
 
and a control cohort (no Rx cohort), of 1000 HCV patients each, were 
followed through the Markov model for a duration of 60 years. The 
cohort was representative of the Seychelles cohort of patients 
infected with hepatitis C by the end of 2016, with the mean age of 
the patients being 32 years, 84% being male and 16% being female 
[11]. 
 
 
Results 
 
Base case analysis: the results showed that treating HCV patients 
with Harvoni (SOF/LDV) was cost-saving as compared to no 
treatment. This is presented in Table 1 below. Treatment was seen 
to have both, a lower cost and higher effectiveness than no 
treatment, consequently dominating the latter. The cost of treatment 
of all hepatitis C cases in Seychelles with DAAs over a period of 60 
years was estimated at € 2,025,834.92, compared to current care 
protocols, which are estimated to cost € 14,702,231.13. Thus, saving 
the payer an estimated € 12,676,396.21, if DAAs are introduced. The 
effect of treatment was 31,758.23 quality adjusted life years (QALYs), 
compared to just 14,938.19 QALYs for the no treatment option. 
Therefore, treatment is preferred, with a gain of 16,820.04 QALYs 
over 60 years. The incremental cost-effectiveness ratio is € 
753.65/QALY, with dominance of the treatment option over the no 
treatment option. The latter was both more expensive and less 
effective. When discounting of costs is not applied, both the costs of 
treatment and no treatment cohorts are higher. This is presented 
in Table 2 below. Furthermore, the cost gap between the two 
treatment options is raised from € 12,676,396.21 to € 25,167,920.84. 
However, these results are presented here for comparison sake 
only. Table 3 and Table 4 below show results for male and female 
subgroups, respectively. The difference in results of the two 
subgroups were driven by the gender differences in general mortality 
rate. Stratification by gender results in the same conclusion of 
treatment with Harvoni being cost saving, as compared to the no 
treatment option, with negative ICER results for both subgroups. 
However, the results show that it is more cost-saving to treat male 
patients than it is to treat female patients, reflected in the lower ICER 
for male group than for female group. This may be explained by the 
lower life expectancy in males for all age-groups. 
  
Sensitivity analysis: due to the lack of primary data from 
Seychelles, there is likely to be considerable uncertainty around the 
ICER estimates. This uncertainty is addressed in probabilistic 
sensitivity analysis (PSA) by varying input parameters according to a 
distribution, as shown in Table 5. The parameters used in this study 
were distributed. Transition probabilities and utility values ranged 
from 0 to 1, and so beta (β) distribution was used to determine their 
distribution. For the determination of distribution of costs, a gamma 
(γ) distribution was used. A simulation using 1000 trials was 
conducted in excel for the probabilistic sensitivity analysis (PSA). The 
PSA results can be presented on a cost-effectiveness plane, as shown 
in Figure 3. The X axis (horizontal axis) measures the incremental 
effect and the Y axis (vertical axis) measures the incremental costs. 
The north-west quadrant represents a situation whereby the new 
treatment is both, costlier and less effective, rendering it dominated 
by no treatment. The south-east quadrant represents a situation 
whereby the new treatment is more effective, being less costly and 
more effective than not treating hepatitis C. The north east and south 
west quadrants are less straightforward, showing a costlier and more 
effective, or a less costly but less effective situation, respectively. In 
these two situations, cost-effectiveness is decided according to 
whether the ICER is above the willingness to pay threshold. Figure 
3 shows that in most of the simulations, the estimated ICER falls into 
the south-east quadrant. Hence, the new treatment with Harvoni is 
more effective and less costly than 'no treatment' option. Most of the 
uncertainty seems to come from the costs, given that the spread of 
data points is wider for costs (vertically) than for QALYs 
(horizontally). Figure 4 shows the cost-effectiveness acceptability 
curve (CEAC) depicting the percentage of the simulation that were 
cost-effective for Harvoni (Neuromuscular blockade (NMB) 
treatment), and for no treatment option (NMB treatment), at different 
willingness to pay thresholds. The different willingness to pay 
threshold presented are approximately one, two, three, and four 
times the GDP per capita of Seychelles in Euro, shown as 13000, 
26000, 39000, 52000, and 65000, respectively. According to the 
CEAC, even at a lower WTP, there is still a high probability (>97%) 
that treatment will be cost-effective, compared with 'no treatment'. 
 
 
Discussion 
 
The results of this study show that treating hepatitis C in Seychelles 
with the direct-acting antiviral (DAAs) Harvoni (SOF/LDV) is cost-
saving, as compared to no treatment, for a time horizon of 60 years. 
This result is robust, as demonstrated by PSA. The study has several 
strengths which support its credibility. Firstly, the country-specific 
data used from Seychelles were representative of the local situation. 
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The simulated cohorts were representative of the cohort of patients 
with HCV infection in Seychelles at the end of 2016, sourced from 
DRSU of the Seychelles Public Health Authority. The costs data of the 
two treatment options were sourced from the Communicable Disease 
Control Unit CDCU budget report, the department responsible for 
follow-up and treatment of HCV patients. This improves the relevance 
of the results to the current Seychelles scenario. Secondly, the 
incorporated conditions are relevant to Seychelles, such as patient 
characteristics, treatment costs as per Seychelles budget report, and 
exclusion of liver transplantation which is not offered in Seychelles. 
This allows the result to be generalisable to Seychelles context. 
Limitations were mostly attributed to availability of disaggregated 
data from Seychelles. Firstly, the risk of re-infection was not 
considered in this model. No new infection entered the model over 
the years either. This may have underestimated the cost of treatment. 
However, the value of treatment through infections prevented was 
also not considered, underestimating the value of treatment in the 
same aspect. In other words, the ability for treatment of one person 
to decrease incidence by decreasing risk of infection to others is not 
valued here. Similarly, other studies reviewed in the literature did not 
capture this value. Secondly, the transition probabilities and utility 
values were from other countries. The EuroQol 5 dimensions 
questionnaire used to report utilities are contextual and involved 
extrapolation from a different setting to Seychelles. Using utility 
questionnaire related to Seychelles would have given a more accurate 
result which are representative of this model of HCV patients in the 
Seychelles context. Thirdly, a single efficacy estimate of Harvoni was 
used, from Alavian et al., minimising its accuracy [12]. Ideally, a 
systematic review result of efficacy should be used. However, such 
publications are limited, given that Harvoni has only been introduced 
within the last few years. The model assumes that the genotypes 
present are sensitive to Harvoni, leading to the possibility of over-
estimating the efficacy of the treatment. 
  
Only direct medical costs were considered, disregarding societal costs 
and consequences. This may have led to undervaluation of the 
treatment, and its ability to decrease travel costs to health centres, 
and increase work production. Furthermore, the lack of a similar study 
in a comparable country to Seychelles, in terms of population size, 
patient profiles, health care system construct, and income per capita, 
makes it a challenge to validate the results. Seychelles is currently 
prioritising patients who are at low risk of re-infection for enrolment 
into the treatment programme [10]. Accessibility to treatment for 
those who are at higher risk of spreading the infection, such as people 
who currently inject drugs and prisoners, remain a challenge. The 
secondary data of HCV patients in Seychelles revealed that 90% were 
People who inject drugs (PWID) and 25% were diagnosed while 
serving a prison sentence [11]. Screening with subsequent treatment 
of high risk patient groups need to be encouraged to slow down 
further transmission rate and decrease incidence. Hopefully, these 
results will motivate the extension of treatment programme to target 
more PWID and prisoners as well. The cost of DAAs remain one of 
the main barriers of HCV treatment. Even if it has been proven that 
treatment is cost-effective, the initial cost of treatment is still high, 
particularly for a developing country. The results of this research 
show how the treatment is not only cost-effective, but cost saving. 
Treatment is an investment, from which benefits will be acquired 
decades later. It is, therefore, tactical to find ways to treat HCV before 
the complications set in. One way to dilute the high initial cost of 
treatment can be to spread it out over years. For example, an aim of 
treating minimum 200 cases per year may be more feasible than 
treating 1000 cases at one time. Policy makers can use these results 
to make evidenced-based decisions on what treatment policy will 
work best for Seychelles. It is noteworthy that from a politician's point 
of view, short-term benefits are more attractive than long term ones. 
Therefore, the initial higher cost of treatment, even after spreading it 
across a few years, remains a strong barrier to policy amendments 
towards treatment of all patients with hepatitis C. Increasing 
awareness amongst health workers and the public may be the 
bottom-up approach required to motivate policy makers to make 
decisions based on scientific evidence. The method of only treating 
patients at low risk of re-infection in Seychelles is arguably the least 
cost-effective method of treatment. The high risk of HCV transmission 
in people who inject drugs (PWID) means that their treatment not 
only decreases their risk of progressing to liver diseases, but also 
decreases the incidence of HCV infection in the general population. 
Treatment of PWID can also be a prevention programme, by 
decreasing risk of transmission of HCV from this person to others. 
One proposed way of reducing the risk of infection in PWID is to use 
the 'treat your friends' approach, proposed by Hellard et al [3]. The 
theory behind this is that most PWID only share needles with a small 
group of other injectors whom they trust [3]. Using this approach of 
treating the whole cluster of injectors at one time reduces risk of re-
infection, as their risk is highly reliant on the HCV status of the people 
they share needles with [3]. 
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Conclusion 
 
In conclusion, the findings of this study demonstrate that treatment 
of hepatitis C cases in Seychelles is cost-saving as opposed to no 
treatment. Additionally, it makes the WHO's goal to eliminate hepatitis 
C as a public health burden by 2030 an achievable one for Seychelles. 
These results make a strong case for expansion of the treatment 
programme in Seychelles to benefit all HCV patients, regardless of 
status of drug injection. Accompanying efficient prevention 
programmes, and an expended screening programme, the treatment 
has the ability to decrease HCV incidence. 
 
What is known about this topic 
 The first all-oral HCV treatment, direct-acting antivirals (DAAs), 
were approved by the European Commission in January 2014; 
 The first all-oral HCV treatment, direct-acting antivirals (DAAs), 
were approved by the European Commission in January 2014; 
 The first all-oral HCV treatment, direct-acting antivirals (DAAs), 
were approved by the European Commission in January 2014. 
What this study adds 
 Cost-effectiveness of treating hepatitis C in an sub-Saharan 
African country and in a Small Island Developing State (SIDS).  
pattern where non-camp resident patients admitted to the IPD, 
present with significantly increased mortality compared to 
camp resident patients might also indicate unaddressed health 
needs in the surrounding area. 
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Table 1: results of Markov Simulation Model (MSM) comparing cost-effectiveness of Harvoni compared to no treatment for 
all HCV patients in Seychelles 
Comparator Cost (€) QALY Incremental cost (€) 
Incremental 
QALY 
ICER 
(cost/QALY) 
Subset 
Rx cohort 2,025,834.92 31,758.23       Dominant 
No Rx cohort 14,702,231.13 14,938.19 -12,676,396.21 16,820.04 -753.65 Dominated 
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Table 2: comparison of results for undiscounted and discounted 
costs 
  Undiscounted 
costs (€) 
Discounted costs 
(€) 
Rx cohort 2,205,770.92 2,025,834.92 
No Rx cohort 25,167,920.84 14,702,231.13 
Incremental costs -22,962,149.92 -12,676,396.21 
 
 
 
 
Table 3: results of Markov Simulation Model comparing cost-effectiveness of Harvoni compared to no treatment for 
male HCV patients in Seychelles 
Comparator Cost (€) QALY 
Incremental 
cost (€) 
Incremental 
QALY 
ICER 
(cost/QALY) 
Subset 
Rx cohort 2,021,905.24 30,713.15       Dominant 
No Rx cohort 14,536,501.25 14,745.26 
-
12,514,596.01 
15,967.89 -783.74 Dominated 
  
 
 
 
Table 4: results of Markov Simulation Model comparing cost-effectiveness of Harvoni compared to no treatment for female HCV 
patients in Seychelles 
Comparator Cost (€) QALY Inc. cost (€) Inc. QALY 
ICER 
(cost/QALY) 
Subset 
Rx cohort 2,046,465.72 37,244.88       Dominant 
No Rx cohort 15,572,312.99 15,951.06 -13,525,847.27 21,293.82 -635.20 Dominated 
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Table 5: parameters used in PSA 
Parameter Deterministic SE Distribution 
P_CHC_SVR 0.977 0.003 Beta 
P_CHC_CC 0.115 0.04106 Beta 
P_CC_DC 0.039 0.04106 Beta 
P_CC_HCC 0.024 0.04106 Beta 
P_DC_HCC 0.014 0.04106 Beta 
P_CHC_Death 
Based on age and 
gender 
Based on age and 
gender 
Beta 
P_CC_Death 
Based on age and 
gender 
Based on age and 
gender 
Beta 
P_DC_Death 0.13 0.02 Beta 
P_HCC_Death 0.43 0.06 Beta 
U_SVR 0.79 0.12 Beta 
U_CHC 0.74 0.03 Beta 
U_CC 0.55 0.1 Beta 
U_DC 0.45 0.06 Beta 
U_HCC 0.45 0.06 Beta 
C_treatment 1377.05 300 Gamma 
C_CHC 256.67 60 Gamma 
C_CC 926.79 200 Gamma 
C_DC 2668.91 600 Gamma 
C_HCC 2955.40 680 Gamma 
P_: transition probability; U_: utility; C_: cost; SE: sampling error; SVR: sustained 
virologic response; CHC: chronic hepatitis C; CC: compensated cirrhosis; DC: 
decopensated cirrhosis; HCC: hepatocellular carcinoma 
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Figure 1: new hepatitis C cases from 2008 to 2016 in Seychelles  
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Figure 2: diagram of Markov model. The health states are Chronic Hepatitis C (CHC), Sustained Virologic Response (SVR), 
Compensated Cirrhosis (CC), death from general mortality (General death), Decompensated Cirrhosis (DC), Hepatocellular Carcinoma 
(HCC), and death due to complications of hepatitis C (Disease-specific death). The arrows indicate the direction of possible transitions 
from one state to another 
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Figure 3: scatter plot of incremental cost-effectiveness of Harvoni (SOF/LDV) as compared to no treatment  
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Figure 4: cost-effectiveness acceptability curve for the simulation 
 
